Product Description
HB-101 is a bivalent recombinant vaccine against human CMV infection.
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hookipa Biotech
Company Location: NEW YORK NY 10016
Company CEO: Joern Aldag
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Cytomegalovirus Infections|Kidney Transplant
Phase 1: Cytomegalovirus Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| H-100-001 | P1 |
Completed |
Cytomegalovirus Infections |
2017-05-01 |
2020-11-30 |
||
| H-100-002 | P2 |
Completed |
Kidney Transplant|Cytomegalovirus Infections |
2022-06-22 |
23% |
2022-08-12 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| 2017-005047-32 | P2 |
Completed |
Kidney Transplant |
2022-06-22 |
23% |
2022-03-13 |
Treatments |